This is a published notice on the Find a Tender service: https://www.find-tender.service.gov.uk/Notice/048165-2025

Contract

BLMK ICB Direct Oral Anticoagulant (DOAC) Medication Review Service

NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board

F03: Contract award notice

Notice identifier: 2025/S 000-048165

Procurement identifier (OCID): ocds-h6vhtk-05867d

Published 12 August 2025, 4:24pm

Section I: Contracting authority

I.1) Name and addresses

NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board

Priory House, Monks Walk, Chicksands

Bedfordshire

SG175TQ

Email

blmkicb.contactus@nhs.net

Country

United Kingdom

Region code

UKH25 - Central Bedfordshire

Internet address(es)

Main address

https://www.bedfordshirelutonandmiltonkeynes.icb.nhs.uk/

Buyer's address

https://www.bedfordshirelutonandmiltonkeynes.icb.nhs.uk/

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

BLMK ICB Direct Oral Anticoagulant (DOAC) Medication Review Service

II.1.2) Main CPV code

• 85121100 - General-practitioner services

II.1.3) Type of contract

Services

II.1.4) Short description

The Direct Oral Anticoagulant (DOAC) medication review service will assist Bedfordshire, Luton and Milton Keynes (BLMK) GP practices to deliver a high quality and safe DOAC review and change programme.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £165,000

II.2) Description

II.2.2) Additional CPV code(s)

• 85100000 - Health services

II.2.3) Place of performance

NUTS codes

• UKJ12 - Milton Keynes

Main site or place of performance

All ICB's geographical regions i.e. Bedfordshire, Luton and Milton Keynes

II.2.4) Description of the procurement

The Direct Oral Anticoagulant (DOAC) medication review service will be delivered by provider employed non-medical prescribing pharmacist with clinical expertise in DOAC prescribing and experience of undertaken similar DOAC review and change programmes. Identifying, reviewing and where appropriate and with patients consent initiating/prescribing a cost-effective DOAC for the patient.

The contact has been awarded following direct award process A with a maximum contract value £165,000 based on £550 per clinical day (7.5hrs) and the contract value is activity related. The contract is for a period of 4 months from 1st September 2025 to 31st December 2025 with an option to extend for a period of up to 3months i.e. 31st March 2026, if required within the specified financial envelope.

II.2.5) Award criteria

Quality criterion - Name: No realistic alternative provider / Weighting: 100

Price - Weighting: 0

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

• The procurement falls outside the scope of application of the regulations

Explanation:

No realistic alternative provider.

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

7 August 2025

V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Spirit Healthcare Ltd

Spirit House, Saffron Way, Leicester

Leicester

LE2 6UP

Telephone

+44 1162865000

Country

United Kingdom

NUTS code

• UKF21 - Leicester

National registration number

06259954

Internet address

www.spirit-health.co.uk

The contractor is an SME

Yes

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £165,000

Total value of the contract/lot: £165,000

Section VI. Complementary information

VI.3) Additional information

This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.

There is a risk of a significant cost pressure to the BLMK ICB prescribing budget through the anticipated loss of a commercial agreement within direct oral anticoagulants (DOACs) prescribing. As a risk mitigation, people on edoxaban within BLMK will be reviewed and where clinically appropriate and with patient consent changed to the most cost-effective DOACs, as identified in NHSE DOAC Commissioning Guidance.

An additional financial risks exists to the BLMK ICB prescribing budget if the review and change programme does not happen at the scale and pace that is required to mitigate loss of the commercial agreement. GP pressures and workforce capacity limitations, means a 3rd party clinical provider with expertise in DOAC prescribing and experience of safely undertaking a DOAC review and change programme is required. Due to the imminent cost pressure there is a need to mobilise the service by 1st September 2025.

The BLMK ICB Chiefs (Executives) gave approval of this in August 2025 at the scheduled Investment Oversight Group Meeting. Conflicts of interest have been managed in line with the ICB's Conflict of Interest and Standards of Business Conduct Policy.

VI.4) Procedures for review

VI.4.1) Review body

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

Email

england.commercialqueries@nhs.net

Country

United Kingdom

Internet address

https://www.england.nhs.uk/